The optimization of targeted therapies against metastatic ERBB2+ BC is challenging for several reasons, including molecular and metabolic adaptations in metastasizing cells, refractive organ-specific microenvironments, and lack of preclinical models to evaluate therapeutic targets [9,46,47,48]. This evidence concerns the gene ERBB2 and breast cancer.